AIC
CBIO

Archer Investment Corporation’s Crescent Biopharma CBIO Stock Holding History

Archer Investment Corporation’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10
Closed -$3.03K – 870
2022
Q4 		$3.03K Buy
+10
New +$1.47K ﹤0.01% 676

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Archer Investment Corporation's CBIO Position: Q1 2023 in Review

Archer Investment Corporation sold out of Crescent Biopharma (CBIO) in Q1 2023, closing a stake of 10 shares — an estimated $3.03K sold.

Archer Investment Corporation first reported a position in CBIO in Q4 2022 and held it in 1 quarter. The position peaked at $3.03K in Q4 2022. 54 funds tracked by Wall St. Rank hold CBIO as of Q1 2023.

  • Archer Investment Corporation reported no remaining Crescent Biopharma position as of Q1 2023 after selling out during the quarter.
  • Archer Investment Corporation sold 10 Crescent Biopharma shares in Q1 2023, an estimated $3.03K.
  • Archer Investment Corporation first reported a position in Crescent Biopharma in Q4 2022 and held it in 1 quarter.
  • Archer Investment Corporation's Crescent Biopharma position peaked at $3.03K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2023.

Based on Archer Investment Corporation's 13F filing for Q1 2023, filed 9 May 2023.